Demethylation of the SBSN gene promoter is associated with metastatic diseases [24], and 5‐AC, a demethylating agent used for MDS treatment, promotes SBSN expression in lung cancer cells via induction of the transcription regulator BORIS [34]. This evidence concerns the gene CTCFL and metastatic neoplasm.